AKBA Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 108083 min ago

@ $1.540

Ausgestellt: 14 Feb 2024 @ 17:12

Rendite: -14.28%

Vorheriges Signal: Feb 14 - 15:30

Vorheriges Signal: Verkaufen

Rendite: -1.28 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 19:35):

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases...

Stats
Tagesvolumen	1.04M
Durchschnittsvolumen	4.86M
Marktkapitalisierung	276.39M
EPS	$0 ( 2024-03-14 )
Nächstes Ertragsdatum	( $-0.0900 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.71
ATR14	$0.00700 (0.53%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-29	Dahan Michel	Sell	8 661	Common Stock
2024-02-29	Hadas Nicole R.	Sell	5 974	Common Stock
2024-02-29	Butler John P.	Sell	46 570	Common Stock
2024-02-29	Burke Steven Keith	Sell	7 169	Common Stock
2024-02-27	Hadas Nicole R.	Sell	7 411	Common Stock

INSIDER POWER
87.62
Last 97 transactions
Buy: 11 050 463 \| Sell: 761 907

Volumen Korrelation

Lang: -0.23 (neutral)

Kurz: -0.50 (neutral)

Signal:(57.065) Neutral

Akebia Therapeutics Inc Korrelation

10 Am meisten positiv korreliert
BNIXU	0.912
AMRB	0.905
NIU	0.904
COFS	0.903
WMG	0.902
APWC	0.895
PFG	0.891
QNRX	0.89
ADPT	0.888
CARE	0.886

10 Am meisten negativ korreliert
LNSR	-0.863
DWSH	-0.863
HAPP	-0.849
XLRN	-0.848
GXII	-0.847
PLMR	-0.846
RCMT	-0.846
LHDX	-0.844
PCRX	-0.843
MTRX	-0.842

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Akebia Therapeutics Inc Korrelation - Währung/Rohstoff

0.00
( neutral )

0.25
( neutral )

Akebia Therapeutics Inc Finanzdaten

Annual	2023
Umsatz:	$194.62M
Bruttogewinn:	$118.89M (61.09 %)
EPS:	$-0.280

FY	2023
Umsatz:	$194.62M
Bruttogewinn:	$118.89M (61.09 %)
EPS:	$-0.280

FY	2022
Umsatz:	$292.60M
Bruttogewinn:	$207.81M (71.02 %)
EPS:	$-0.580

FY	2021
Umsatz:	$213.58M
Bruttogewinn:	$60.18M (28.18 %)
EPS:	$-1.700

Financial Reports:

No articles found.

Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.